✦ LIBER ✦
CN3 PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRATIFICATION
✍ Scribed by M Pompen; A Novak; P Postmus; M Gok; M Gyldmark
- Book ID
- 119594102
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 67 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1098-3015
No coin nor oath required. For personal study only.